PARIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery ...
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology ...
– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...
Vonaprument Has the Potential to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Visual Structures BRISBANE, Calif., ...
A new study published in Nature Communications reveals the specific genetic factors linked to the presence of reticular ...
A laser treatment for this common eye disease will start clinical trials in Finland next spring ––researchers hope it could be available to sufferers in as little as three years Around a third of ...
Approaching her 91st birthday, Dame Judi Dench has offered a poignant insight into her worsening eyesight, describing the decline as "crushing". The beloved actress, who was first diagnosed with ...
There is strong interest across many stakeholders to increase progress around developing treatments for dry age-related macular degeneration (AMD). Advancements in drug discovery and development in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback